Donor Screening Recommendations To Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability; Correction

---
identifier: "/us/fr/2016-08330"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Donor Screening Recommendations To Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability; Correction"
title_number: 0
title_name: "Federal Register"
section_number: "2016-08330"
section_name: "Donor Screening Recommendations To Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability; Correction"
positive_law: false
currency: "2016-04-12"
last_updated: "2016-04-12"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Health and Human Services Department"
document_number: "2016-08330"
document_type: "notice"
publication_date: "2016-04-12"
agencies:
  - "Health and Human Services Department"
  - "Food and Drug Administration"
fr_citation: "81 FR 21577"
fr_volume: 81
docket_ids:
  - "Docket No. FDA-2016-D-0768"
fr_action: "Notice of availability; correction."
---


#  Donor Screening Recommendations To Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability; Correction

**AGENCY:**

Food and Drug Administration, HHS.

**ACTION:**

Notice of availability; correction.

**SUMMARY:**

The Food and Drug Administration (FDA) is correcting a notice that appeared in the *Federal Register* of Monday, March 7, 2016 (81 FR 11808). The document announced a guidance for industry entitled “Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products.” The document was published with an incorrect docket number in the *ADDRESSES* section. This document corrects that error.

**FOR FURTHER INFORMATION CONTACT:**

Lisa Granger, Office of Policy, Planning, Legislation, and Analysis, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver Spring, MD 20993-0002, 301-796-9115.

**SUPPLEMENTARY INFORMATION:**

In FR Doc. 2016-04893, appearing on page 11808 in the *Federal Register* of Monday, March 7, 2016, the following correction is made:

1. On page 11808, in the third column, the docket number is corrected to read “FDA-2016-D-0768”.

Dated: April 6, 2016.

Leslie Kux,

Associate Commissioner for Policy.